Yıl: 2015 Cilt: 15 Sayı: 7 Sayfa Aralığı: 577 - 585 Metin Dili: İngilizce İndeks Tarihi: 29-07-2022

The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol

Öz:
Objective: Catestatin has several cardiovascular actions, in addition to diminished sympatho-adrenal flow. Decreased plasma catestatin levelsmay reflect a predisposition for the development of hypertension and metabolic disorders. We planned to investigate the possible roles ofcatestatin in untreated hypertensive patients. As a secondary objective, we compared catestatin concentrations of healthy subjects with thoseof hypertensive patients in order to understand whether catestatin is increased reactively or diminished at onset. Methods: Our study was cross-sectional and observational. The patient group, comprising 109 consecutive untreated hypertensive patientswithout additional systemic or coronary heart disease, underwent evaluations of plasma catestatin, waist circumference, lipid parameters, leftventricular mass, carotid intima-media thickness, and flow-mediated dilation of the brachial artery. Additionally, we measured catestatin con- centrations of 38 apparently healthy subjects without any disease using a commercial enzyme-linked immunosorbent assay kit. Results: We documented increased catestatin concentrations in previously untreated hypertensive patients compared to healthy controls (2.27±0.83vs. 1.92±0.49 ng/mL, p=0.004). However, this association became insignificant after adjustments for age, gender, height, and weight. Within the patientgroup, catestatin levels were significantly higher in females. Among all study parameters, age, high-density lipoprotein cholesterol (HDL-C) corre- lated positively to plasma catestatin, whereas triglycerides, hemoglobin, and left ventricular mass correlated negatively to plasma catestatin. Wecould not detect an association between vascular parameters and catestatin. Catestatin levels were significantly elevated with increasing HDL-C(1.91±0.37, 2.26±0.79, and 3.1±1.23 ng/mL in patients with HDL-C <40, 40-60, and >60 mg/dL, respectively). Multiple linear regression analysis revealedage (beta: 0.201, p=0.041) and HDL-C (beta: 0.390, p<0.001) as independent correlates of plasma catestatin concentration. Additionally, male gender(beta:-0.330, p=0.001) and plasma catestatin (beta: 0.299, p=0.002) were significantly associated with HDL-C concentrations. Conclusion: We documented that plasma catestatin is an independent predictor of high-density lipoprotein cholesterol. In addition to antihy- pertensive effects, catestatin appears to be related to improved lipid and metabolic profiles. Coexistence of low catestatin levels with lowHDL-C may provide a probable mechanism for the predictive value of low HDL-C for increased hypertension and cardiovascular events.
Anahtar Kelime:

Konular: Kalp ve Kalp Damar Sistemi
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • 1. Helle KB. The chromogranin A-derived peptides vasostatin-I and catestatin as regulatory peptides for cardiovascular functions. Cardiovasc Res 2010; 85: 9-16. [CrossRef]
  • 2. Mahata SK, Mahata M, Fung MM, O’Connor DT. Catestatin: a mul- tifunctional peptide from chromogranin A. Regul Pept 2010; 162: 33-43. [CrossRef]
  • 3. Mahata SK, O’Connor DT, Mahata M, Yoo SH, Taupenot L, Wu H, et al. Novel autocrine feedback control of catecholamine release. A discrete chromogranin a fragment is a noncompetitive nicotinic cholinergic antagonist. J Clin Invest 1997; 100: 1623-33. [CrossRef]
  • 4. Mahata SK, Mahata M, Parmer RJ, O’Connor DT. Desensitization of catecholamine release. The novel catecholamine release-inhibito- ry peptide catestatin (chromogranin a344-364) acts at the receptor to prevent nicotinic cholinergic tolerance. J Biol Chem 1999; 274: 2920-8. [CrossRef]
  • 5. Rao F, Wen G, Gayen JR, Das M, Vaingankar SM, Rana BK, et al. Catecholamine release-inhibitory peptide catestatin (chromo- granin A(352-372)): naturally occurring amino acid variant Gly364Ser causes profound changes in human autonomic activity and alters risk for hypertension. Circulation 2007; 115: 2271-81. [CrossRef]
  • 6. Mahata SK, Mahata M, Wen G, Wong WB, Mahapatra NR, Hamilton BA, et al. The catecholamine release-inhibitory “cates- tatin” fragment of chromogranin a: naturally occurring human variants with different potencies for multiple chromaffin cell nico- tinic cholinergic responses. Mol Pharmacol 2004; 66: 1180-91. [CrossRef]
  • 7. O’Connor DT, Kailasam MT, Kennedy BP, Ziegler MG, Yanaihara N, Parmer RJ. Early decline in the catecholamine release-inhibitory peptide catestatin in humans at genetic risk of hypertension. J Hypertens 2002; 20: 1335-45. [CrossRef]
  • 8. Delles C, Padmanabhan S. Genetics and hypertension: is it time to change my practice? Can J Cardiol 2012; 28: 296-304. [CrossRef]
  • 9. Cheung BM, Li C. Diabetes and hypertension: is there a common metabolic pathway? Curr Atheroscler Rep 2012; 14: 160-6. [CrossRef]
  • 10. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-52. [CrossRef]
  • 11. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-8. [CrossRef]
  • 12. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002; 39: 257-65. [CrossRef]
  • 13. Kruger PG, Mahata SK, Helle KB. Catestatin (CgA344-364) stimu- lates rat mast cell release of histamine in a manner comparable to mastoparan and other cationic charged neuropeptides. Regul Pept 2003; 114: 29-35. [CrossRef]
  • 14. Mineo C, Shaul PW. Novel biological functions of high-density lipoprotein cholesterol. Circ Res 2012; 111: 1079-90. [CrossRef]
  • 15. Bandyopadhyay GK, Vu CU, Gentile S, Lee H, Biswas N, Chi NW, et al. Catestatin (chromogranin A(352-372)) and novel effects on mobi- lization of fat from adipose tissue through regulation of adrenergic and leptin signaling. J Biol Chem 2012; 287: 23141-51. [CrossRef]
  • 16. Verghese PB, Arrese EL, Soulages JL. Stimulation of lipolysis enhances the rate of cholesterol efflux to HDL in adipocytes. Mol Cell Biochem 2007; 302: 241-8. [CrossRef]
  • 17. Zhang Y, McGillicuddy FC, Hinkle CC, O’Neill S, Glick JM, Rothblat GH, et al. Adipocyte modulation of high-density lipoprotein choles- terol. Circulation 2010; 121: 1347-55. [CrossRef]
  • 18. Mahapatra NR, O’Connor DT, Vaingankar SM, Hikim AP, Mahata M, Ray S, et al. Hypertension from targeted ablation of chromogranin A can be rescued by the human ortholog. J Clin Invest 2005; 115: 1942-52. [CrossRef]
  • 19. Gayen JR, Gu Y, O’Connor DT, Mahata SK. Global disturbances in autonomic function yield cardiovascular instability and hyperten- sion in the chromogranin a null mouse. Endocrinology 2009; 150: 5027-35. [CrossRef]
  • 20. Kennedy BP, Mahata SK, O’Connor DT, Ziegler MG. Mechanism of cardiovascular actions of the chromogranin A fragment catestatin in vivo. Peptides 1998; 19: 1241-8. [CrossRef]
  • 21. Fung MM, Salem RM, Mehtani P, Thomas B, Lu CF, Perez B, et al. Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. Clin Exp Hypertens 2010; 32: 278-87. [CrossRef]
  • 22. Papakonstantinou NA, Stamou MI, Baikoussis NG, Goudevenos J, Apostolakis E. Sex differentiation with regard to coronary artery disease. J Cardiol 2013; 62: 4-11. [CrossRef]
  • 23. Meng L, Ye XJ, Ding WH, Yang Y, Di BB, Liu L, et al. Plasma cate- cholamine release-inhibitory peptide catestatin in patients with essential hypertension. J Cardiovasc Med (Hagerstown) 2011; 12: 643-7. [CrossRef]
  • 24. Schillaci G, De Vuono S, Pucci G. An endogenous brake on the sympathetic nervous system: the emerging role of catestatin in hypertension. J Cardiovasc Med 2011; 12: 609-12. [CrossRef]
  • 25. Gamboa A, Okamoto LE, Diedrich A, Choi L, Robertson D, Farley G, et al. Sympathetic activation and nitric oxide function in early hypertension. Am J Physiol Heart Circ Physiol 2012; 302: H1438-43. [CrossRef]
  • 26. Seals DR, Esler MD. Human ageing and the sympathoadrenal system. J Physiol 2000; 528: 407-17. [CrossRef]
APA Durakoglugil M, AYAZ T, KOCAMAN S, Kırbaş A, DURAKOĞLUGİL T, ERDOĞAN T, ÇETİN M, ŞAHİN O, çiçek y (2015). The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. , 577 - 585.
Chicago Durakoglugil Murtaza Emre,AYAZ Teslime,KOCAMAN Sinan Altan,Kırbaş Aynur,DURAKOĞLUGİL Tuğba,ERDOĞAN Turan,ÇETİN Mustafa,ŞAHİN Osman Zikrullah,çiçek yüksel gülen The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. (2015): 577 - 585.
MLA Durakoglugil Murtaza Emre,AYAZ Teslime,KOCAMAN Sinan Altan,Kırbaş Aynur,DURAKOĞLUGİL Tuğba,ERDOĞAN Turan,ÇETİN Mustafa,ŞAHİN Osman Zikrullah,çiçek yüksel gülen The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. , 2015, ss.577 - 585.
AMA Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. . 2015; 577 - 585.
Vancouver Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. . 2015; 577 - 585.
IEEE Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y "The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol." , ss.577 - 585, 2015.
ISNAD Durakoglugil, Murtaza Emre vd. "The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol". (2015), 577-585.
APA Durakoglugil M, AYAZ T, KOCAMAN S, Kırbaş A, DURAKOĞLUGİL T, ERDOĞAN T, ÇETİN M, ŞAHİN O, çiçek y (2015). The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology, 15(7), 577 - 585.
Chicago Durakoglugil Murtaza Emre,AYAZ Teslime,KOCAMAN Sinan Altan,Kırbaş Aynur,DURAKOĞLUGİL Tuğba,ERDOĞAN Turan,ÇETİN Mustafa,ŞAHİN Osman Zikrullah,çiçek yüksel gülen The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology 15, no.7 (2015): 577 - 585.
MLA Durakoglugil Murtaza Emre,AYAZ Teslime,KOCAMAN Sinan Altan,Kırbaş Aynur,DURAKOĞLUGİL Tuğba,ERDOĞAN Turan,ÇETİN Mustafa,ŞAHİN Osman Zikrullah,çiçek yüksel gülen The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology, vol.15, no.7, 2015, ss.577 - 585.
AMA Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology. 2015; 15(7): 577 - 585.
Vancouver Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol. The Anatolian Journal of Cardiology. 2015; 15(7): 577 - 585.
IEEE Durakoglugil M,AYAZ T,KOCAMAN S,Kırbaş A,DURAKOĞLUGİL T,ERDOĞAN T,ÇETİN M,ŞAHİN O,çiçek y "The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol." The Anatolian Journal of Cardiology, 15, ss.577 - 585, 2015.
ISNAD Durakoglugil, Murtaza Emre vd. "The relationship of plasma catestatin concentrations with metabolic and vascular parameters in untreated hypertensive patients: Influence on high-density lipoprotein cholesterol". The Anatolian Journal of Cardiology 15/7 (2015), 577-585.